<DOC>
	<DOC>NCT02209987</DOC>
	<brief_summary>This study will estimate the absolute bioavailability of subcutaneously injected GS-5745, characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after subcutaneous (SC) injection and intravenous (IV) administration, and evaluate the formation of anti-GS-5745 antibodies after SC and IV administration.</brief_summary>
	<brief_title>Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<criteria>In the opinion of the investigator, individuals must be in good general health based upon medical history and physical examination Females, of childbearing potential, and males must agree to utilize protocol specific contraception methods Screening laboratory evaluations must be within defined thresholds Infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) Pregnant and lactating females History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with individual treatment and/or adherence to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>